Organization
Intermountain Healthcare
7 abstracts
Abstract
Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Michigan Cancer Research Consortium, City of Hope - Chicago, Division of Hematology and Oncology, Department of Medicine, O’Neal Comprehensive Cancer Center of University of Alabama at Birmingham, Heersink School of Medicine, Intermountain Healthcare, Cancer Research Consortium of West Michigan,
Abstract
Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Sutter Health, Intermountain Healthcare, Mayo Clinic,
Abstract
SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.Org: BCCancer, Multicare Auburn Medical Center, Intermountain Healthcare, Indiana University Simon Comprehensive Cancer Center, Center for Data Intensive Science at the University of Chicago,
Abstract
Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, American Society of Clinical Oncology, Herbert-Herman Cancer Center, Michigan Cancer Research Consortium,
Abstract
Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Herbert-Herman Cancer Center, Michigan Cancer Research Consortium, American Society of Clinical Oncology, Cancer Treatment Centers of America – Chicago, part of City of Hope, Levine Cancer Institute,
Abstract
Clinical characteristics of interval breast cancer within 12 months and 13-24 months in Utah.Org: University of Utah, Intermountain Healthcare, Hunstman Cancer Institute at the University of Utah, University of Utah Division of Genetic Epidemiology,
Abstract
Use of molecular NGS vs single gene testing differs by clinical setting and physician’s specialty in mNSCLC management.Org: Diaceutics Plc, Diaceutics, Intermountain Healthcare,